Market reactionShares fell 10% on Nov 5.
Lexeo Therapeutics is a clinical-stage genetic medicine company developing LX2006, a gene therapy for the heart disease of Friedreich ataxia, and LX2020 for PKP2 arrhythmogenic cardiomyopathy; none are approved.
Lexeo's case rests on LX2006, an intravenous AAV gene therapy with Breakthrough Therapy designation for the cardiomyopathy of Friedreich ataxia. The pivotal SUNRISE-FA 2 compares 13 treated participants with 13 untreated controls on left ventricular mass index, with topline data expected in the second half of 2027. A potential BLA under accelerated approval could follow in the first half of 2028, and cash of $234.2 million is expected to last into 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: LX2006 reduces LVMI in SUNRISE-FA 2
Does LX2006 reduce LVMI versus untreated controls enough to support accelerated approval?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Lexeo's pivotal SUNRISE-FA 2 trial of LX2006 is enrolling toward 2H 2027 data and a 1H 2028 BLA for accelerated approval
BTD-backed gene therapy for a fatal heart complication of Friedreich ataxia heads to a 26-patient pivotal trial — approvability on a single-arm-adjacent external-control design is the deciding question
LX2006's registrational SUNRISE-FA 2 readout will determine whether Breakthrough-designated AAV gene therapy reaches BLA submission for Friedreich ataxia cardiomyopathy
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases, Neurology and pain, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.